LONG-TERM TOXICITY OF ANTITHYMOCYTE GLOBULIN INDUCTION MAY VARY WITH CHOICE OF AGENT: A SINGLE-CENTER RETROSPECTIVE STUDY
- 1 April 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 77 (7), 1029-1033
- https://doi.org/10.1097/01.tp.0000116442.81259.60
Abstract
Antithymocyte globulin (ATG) preparations are frequently used as induction treatment in renal transplantation, but little is known about the clinical equivalence of these different agents. We performed a retrospective, single-center study to compare the long-term clinical effects of ATG Fresenius (ATGF) and Thymoglobulin (SangStat, Fremont, CA) in renal transplant recipients. A total of 194 consecutive renal transplant recipients were included who had undergone transplantation in our center between June 1993 and April 2001 and had received ATGF or Thymoglobulin as induction treatment. A total of 129 patients received ATGF and 65 patients received Thymoglobulin. Thirty patients (23%) in the ATGF group demonstrated cytomegalovirus (CMV) disease, whereas 24 patients (37%) in the Thymoglobulin group demonstrated CMV (P =0.02). Five patients (3.9%) in the ATGF group and eight patients (12.3%) in the Thymoglobulin group developed posttransplant malignancy (P =0.01). Five patients (3.9%) in the ATGF group and nine patients (13.8%) in the Thymoglobulin group died during follow-up (P =0.005). Cox regression analysis revealed that Thymoglobulin was an independent predictor of CMV disease (relative risk [RR] 2.16, confidence interval [CI] 95% [1.04–4.48]), malignancy (RR 2.16, CI 95% [1.04–4.48]), and death (RR 4.14, CI 95% [1.36–12.6]). In renal transplant recipients, induction therapy with Thymoglobulin seems to be associated with a significantly greater incidence of CMV disease, malignancy, and death compared with ATGF.Keywords
This publication has 14 references indexed in Scilit:
- Cancer incidence in a kidney-transplanted populationTransplant International, 2000
- A RANDOMIZED, DOUBLE-BLINDED COMPARISON OF THYMOGLOBULIN VERSUS ATGAM FOR INDUCTION IMMUNOSUPPRESSIVE THERAPY IN ADULT RENAL TRANSPLANT RECIPIENTS1,2Transplantation, 1999
- RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2Transplantation, 1998
- A randomized clinical trial using ATG fresenius or ATG merieux as induction therapy in kidney transplantationTransplantation Proceedings, 1997
- Effect of anti-lymphocyte induction therapy on renal allograft survivalJournal of the American Society of Nephrology, 1997
- A prospective study on efficacy and tolerance of antithymocyte globulin fresenius versus thymoglobuline merieux after renal transplantationTransplantation Proceedings, 1997
- Malignancies after renal transplantation: the EDTA-ERA registry experienceNephrology Dialysis Transplantation, 1995
- Cytomegalovirus Infection Rate among Heart Transplant Patients in Relation to Anti-thymocyte Immunoglobulin Induction TherapyScandinavian Journal of Infectious Diseases, 1994
- Incidence of non-hodgkin lymphoma in kidney and heart transplant recipientsThe Lancet, 1993
- Antiproliferative effect of antilymphocyte globulins on B cells and B- cell linesBlood, 1992